Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases

References

• Clagett-Dame M, DeLuca HF. The role of vitamin A in mammalian reproduction and embryonic development. Annu Rev Nutr 2002;22:347–81
   PubMed Web of Science ®Google Scholar
• Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980;605:33–91
   PubMed Web of Science ®Google Scholar
• Maden M. Retinoid signalling in the development of the central nervous system. Nat Rev Neurosci 2002;3:843–53
   PubMed Web of Science ®Google Scholar
• McCaffery P, Drager UC. Regulation of retinoic acid signaling in the embryonic nervous system: a master differentiation factor. Cytokine Growth Factor Rev 2000;11:233–49
   PubMed Web of Science ®Google Scholar
• Ross SA, McCaffery PJ, Drager UC, De Luca LM. Retinoids in embryonal development. Physiol Rev 2000;80:1021–54
   PubMed Web of Science ®Google Scholar
• Sporn MB, Roberts AB. Role of retinoids in differentiation and carcinogenesis. J Natl Cancer Inst 1984;73:1381–7
   PubMedGoogle Scholar
• di Masi A, Leboffe L, De Marinis E, et al. Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol Aspects Med 2015;41:1–115
   PubMed Web of Science ®Google Scholar
• Levin AA, Sturzenbecker LJ, Kazmer S, et al. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature 1992;355:359–61
   PubMed Web of Science ®Google Scholar
• Mangelsdorf DJ, Borgmeyer U, Heyman RA, et al. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 1992;6:329–44
   PubMed Web of Science ®Google Scholar
• Mark M, Ghyselinck NB, Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu Rev Pharmacol Toxicol 2006;46:451–80
   PubMed Web of Science ®Google Scholar
• Altucci L, Leibowitz MD, Ogilvie KM, et al. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793–810
   PubMed Web of Science ®Google Scholar
• Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell 2008;134:921–31
   PubMed Web of Science ®Google Scholar
• Niederreither K, Dolle P. Retinoic acid in development: towards an integrated view. Nat Rev Genet 2008;9:541–53
   PubMed Web of Science ®Google Scholar
• Lutz JD, Dixit V, Yeung CK, et al. Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. Biochem Pharmacol 2009;77:258–68
   PubMed Web of Science ®Google Scholar
• Ray WJ, Bain G, Yao M, Gottlieb DI. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J Biol Chem 1997;272:18702–8
   PubMed Web of Science ®Google Scholar
• Ross AC, Zolfaghari R. Cytochrome P450s in the regulation of cellular retinoic acid metabolism. Annu Rev Nutr 2011;31:65–87
   PubMed Web of Science ®Google Scholar
• Thatcher JE, Isoherranen N. The role of CYP26 enzymes in retinoic acid clearance. Expert Opin Drug Metab Toxicol 2009;5:875–86
   PubMed Web of Science ®Google Scholar
• Thatcher JE, Zelter A, Isoherranen N. The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. Biochem Pharmacol 2010;80:903–12
   PubMed Web of Science ®Google Scholar
• Nelson CH, Buttrick BR, Isoherranen N. Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics. Curr Top Med Chem 2013;13:1402–28
   PubMed Web of Science ®Google Scholar
• Tay S, Dickmann L, Dixit V, Isoherranen N. A comparison of the roles of peroxisome proliferator-activated receptor and retinoic acid receptor on CYP26 regulation. Mol Pharmacol 2010;77:218–27
   PubMed Web of Science ®Google Scholar
• Topletz AR, Thatcher JE, Zelter A, et al. Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases. Biochem Pharmacol 2012;83:149–63
   PubMed Web of Science ®Google Scholar
• Wang Y, Zolfaghari R, Ross AC. Cloning of rat cytochrome P450RAI (CYP26) cDNA and regulation of its gene expression by all-trans-retinoic acid in vivo. Arch Biochem Biophys 2002;401:235–43
   PubMed Web of Science ®Google Scholar
• White JA, Ramshaw H, Taimi M, et al. Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism. Proc Natl Acad Sci USA 2000;97:6403–8
   PubMed Web of Science ®Google Scholar
• Xi J, Yang Z. Expression of RALDHs (ALDH1As) and CYP26s in human tissues and during the neural differentiation of P19 embryonal carcinoma stem cell. Gene Expr Patterns 2008;8:438–42
   PubMed Web of Science ®Google Scholar
• Taimi M, Helvig C, Wisniewski J, et al. A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid. J Biol Chem 2004;279:77–85
   PubMed Web of Science ®Google Scholar
• Ahmad N, Mukhtar H. Cytochrome P450: a target for drug development for skin diseases. J Invest Dermatol 2004;123:417–25
   PubMed Web of Science ®Google Scholar
• Kuenzli S, Saurat JH. Retinoids for the treatment of psoriasis: outlook for the future. Curr Opin Investig Drugs 2001;2:625–30
   PubMedGoogle Scholar
• Miller WH. Jr. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 1998;83:1471–82
   PubMed Web of Science ®Google Scholar
• Njar VC. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Rev Med Chem 2002;2:261–9
   PubMed Web of Science ®Google Scholar
• Njar VC, Gediya L, Purushottamachar P, et al. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem 2006;14:4323–40
   PubMed Web of Science ®Google Scholar
• Verfaille CJ, Borgers M, van Steensel MA. Retinoic acid metabolism blocking agents (RAMBAs): a new paradigm in the treatment of hyperkeratotic disorders. J Dtsch Dermatol Ges 2008;6:355–64
   PubMed Web of Science ®Google Scholar
• Gomaa MS, Bridgens CE, Illingworth NA, et al. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold. Bioorg Med Chem 2012;20:4201–7
   PubMed Web of Science ®Google Scholar
• Le Borgne M, Marchand P, Le Baut G, et al. Retinoic acid metabolism inhibition by 3-azolylmethyl-1H-indoles and 2, 3 or 5-(alpha-azolylbenzyl)-1H-indoles. J Enzyme Inhib Med Chem 2003;18:155–8
   PubMed Web of Science ®Google Scholar
• Sun B, Liu K, Han J, et al. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors. Bioorg Med Chem 2015;23:6763–73
   PubMed Web of Science ®Google Scholar
• Purushottamachar P, Patel JB, Gediya LK, et al. First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds. Eur J Med Chem 2012;47:412–23
   PubMed Web of Science ®Google Scholar
• Sun B, Song S, Hao CZ, et al. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents. J Mol Graph Model 2015;56:10–19
   PubMed Web of Science ®Google Scholar
• Gomaa MS, Armstrong JL, Bobillon B, et al. Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem 2008;16:8301–13
   PubMed Web of Science ®Google Scholar
• Gomaa MS, Bridgens CE, Aboraia AS, et al. Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates. J Med Chem 2011;54:2778–91
   PubMed Web of Science ®Google Scholar
• Thatcher JE, Buttrick B, Shaffer SA, et al. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase. Mol Pharmacol 2011;80:228–39
   PubMed Web of Science ®Google Scholar
• De Coster R, Wouters W, Van Ginckel R, et al. Experimental studies with liarozole (R 75,251): an antitumoral agent which inhibits retinoic acid breakdown. J Steroid Biochem Mol Biol 1992;43:197–201
   PubMed Web of Science ®Google Scholar
• Karonen T, Neuvonen PJ, Backman JT. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br J Clin Pharmacol 2012;73:257–67
   PubMed Web of Science ®Google Scholar
• Lai XS, Yang LP, Li XT, et al. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metabol 2009;10:1009–47
   PubMed Web of Science ®Google Scholar
• Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005;77:341–52
   PubMed Web of Science ®Google Scholar
• VandenBrink BM, Foti RS, Rock DA, et al. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metabol Dispos 2011;39:1546–54
   PubMed Web of Science ®Google Scholar
• Marill J, Capron CC, Idres N, Chabot GG. Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Biochem Pharmacol 2002;63:933–43
   PubMed Web of Science ®Google Scholar
• Marill J, Idres N, Capron CC, et al. Retinoic acid metabolism and mechanism of action: a review. Curr Drug Metabol 2003;4:1–10
   PubMed Web of Science ®Google Scholar
• McSorley LC, Daly AK. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol 2000;60:517–26
   PubMed Web of Science ®Google Scholar
• Nadin L, Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol 1999;58:1201–8
   PubMed Web of Science ®Google Scholar
• Rowbotham SE, Boddy AV, Redfern CP, et al. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metabol Dispos 2010;38:1261–6
   PubMed Web of Science ®Google Scholar
• Nath A, Zientek MA, Burke BJ, et al. Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors. Drug Metabol Dispos 2010;38:2195–203
   PubMed Web of Science ®Google Scholar
• Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005;45:68–78
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002;72:685–91
   PubMed Web of Science ®Google Scholar
• Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metabol Dispos 2011;39:1977–86
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Granfors M, et al. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003;46:1319–23
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen M, et al. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther 2008;84:403–11
   PubMed Web of Science ®Google Scholar
• Schoch GA, Yano JK, Wester MR, et al. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 2004;279:9497–503
   PubMed Web of Science ®Google Scholar
• Schoch GA, Yano JK, Sansen S, et al. Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 2008;283:17227–37
   PubMed Web of Science ®Google Scholar
• Kerdpin O, Elliot DJ, Boye SL, et al. Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry 2004;43:7834–42
   PubMed Web of Science ®Google Scholar
• Melet A, Marques-Soares C, Schoch GA, et al. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry 2004;43:15379–92
   PubMed Web of Science ®Google Scholar
• Foti RS, Isoherranen N, Zelter A, et al. Identification of tazarotenic acid as the first xenobiotic substrate of human retinoic acid hydroxylase CYP26A1 and CYP26B1. J Pharm Exp Ther 2016;357:281–92
   PubMed Web of Science ®Google Scholar
• Sherman W, Beard HS, Farid R. Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des 2006;67:83–4
   PubMed Web of Science ®Google Scholar
• Sherman W, Day T, Jacobson MP, et al. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006;49:534–53
   PubMed Web of Science ®Google Scholar
• Gleiter CH, Morike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002;41:7–17
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Kunka RL, Yin Y, et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004;60:265–8
   PubMed Web of Science ®Google Scholar
• Brunton LL, Lazo JS, Parker KL, editors. Goodman, Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill Companies, Inc; 2006
   Google Scholar
• Saperstein S, Edgren RA, Lee GJ, et al. Bioequivalence of two oral contraceptive drugs containing norethindrone and ethinyl estradiol. Contraception 1989;40:581–90
   PubMed Web of Science ®Google Scholar
• Uchida S, Shimada K, Misaka S, et al. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. Drug Metabol Pharmacokinet 2010;25:605–10
   PubMed Web of Science ®Google Scholar
• DrugBank: Open Data Drug and Drug Target Database. Version 4.5. Available from: http://www.drugbank.ca/ [last accessed 19 May 2015]
   Google Scholar
• Deshpande. Evaluation of topical bioavailability of clotrimazole using dermatoPharmacoKinetic method. Int J Sci Inv Today 2013;2:216–25
   Google Scholar
• Boulton DW, Walle UK, Walle T. Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol 1998;50:243–9
   PubMed Web of Science ®Google Scholar
• Karonen T, Neuvonen PJ, Backman JT. The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. Eur J Clin Pharmacol 2011;67:151–5
   PubMed Web of Science ®Google Scholar
• Moon YJ, Wang L, DiCenzo R, Morris ME. Quercetin pharmacokinetics in humans. Biopharm Drug Dispos 2008;29:205–17
   PubMed Web of Science ®Google Scholar
• Walter-Sack I, de Vries JX, Ittensohn A, et al. Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone. Klinische Wochenschrift 1988;66:160–6
   PubMedGoogle Scholar
• Buttrick BR. Characterization of selective and potent inhibitors of the human retinoic acid hydroxylases CYP26A1 and CYP26B1. Seattle (WA): University of Washington; 2012
   Google Scholar
• Marill J, Cresteil T, Lanotte M, Chabot GG. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 2000;58:1341–8
   PubMed Web of Science ®Google Scholar
• Gomaa MS, Yee SW, Milbourne CE, et al. Homology model of human retinoic acid metabolising enzyme cytochrome P450 26A1 (CYP26A1): active site architecture and ligand binding. J Enzyme Inhib Med Chem 2006;21:361–9
   PubMed Web of Science ®Google Scholar
• Karlsson M, Strid Å, Sirsjö A, Eriksson LA. Homology models and molecular modeling of human retinoic acid metabolizing enzymes cytochrome P450 26A1 (CYP26A1) and P450 26B1 (CYP26B1). J Chem Theory Comput 2008;4:1021–7
   PubMed Web of Science ®Google Scholar
• Asselineau D, Bernard BA, Bailly C, Darmon M. Retinoic acid improves epidermal morphogenesis. Dev Biol 1989;133:322–35
   PubMed Web of Science ®Google Scholar
• Cunningham TJ, Duester G. Mechanisms of retinoic acid signalling and its roles in organ and limb development. Nat Rev Mol Cell Biol 2015;16:110–23
   PubMed Web of Science ®Google Scholar
• Ransom J, Morgan PJ, McCaffery PJ, Stoney PN. The rhythm of retinoids in the brain. J Neurochem 2014;129:366–76
   PubMed Web of Science ®Google Scholar
• Raverdeau M, Gely-Pernot A, Feret B, et al. Retinoic acid induces Sertoli cell paracrine signals for spermatogonia differentiation but cell autonomously drives spermatocyte meiosis. Proc Natl Acad Sci USA 2012;109:16582–7
   PubMed Web of Science ®Google Scholar
• Raverdeau M, Mills KH. Modulation of T cell and innate immune responses by retinoic acid. J Immunol 2014;192:2953–8
   PubMed Web of Science ®Google Scholar
• Chen H, Howald WN, Juchau MR. Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes. Drug Metabol Dispos 2000;28:315–22
   PubMed Web of Science ®Google Scholar
• Roos TC, Jugert FK, Merk HF, Bickers DR. Retinoid metabolism in the skin. Pharmacol Rev 1998;50:315–33
   PubMed Web of Science ®Google Scholar
• Zhang QY, Dunbar D, Kaminsky L. Human cytochrome P-450 metabolism of retinals to retinoic acids. Drug Metabol Dispos 2000;28:292–7
   PubMed Web of Science ®Google Scholar
• Chen H, Fantel AG, Juchau MR. Catalysis of the 4-hydroxylation of retinoic acids by cyp3a7 in human fetal hepatic tissues. Drug Metabol Dispos 2000;28:1051–7
   PubMed Web of Science ®Google Scholar
• Helvig C, Taimi M, Cameron D, et al. Functional properties and substrate characterization of human CYP26A1, CYP26B1, and CYP26C1 expressed by recombinant baculovirus in insect cells. J Pharmacol Toxicol Methods 2011;64:258–63
   PubMed Web of Science ®Google Scholar
• Leo MA, Lasker JM, Raucy JL, et al. Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Arch Biochem Biophys 1989;269:305–12
   PubMed Web of Science ®Google Scholar
• Sonneveld E, van den Brink CE, van der Leede BM, et al. Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Differ 1998;9:629–37
   PubMedGoogle Scholar
• Yamazaki H, Shimada T. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica 1999;29:231–41
   PubMed Web of Science ®Google Scholar
• Shimshoni JA, Roberts AG, Scian M, et al. Stereoselective formation and metabolism of 4-hydroxy-retinoic Acid enantiomers by cytochrome p450 enzymes. J Biol Chem 2012;287:42223–32
   PubMed Web of Science ®Google Scholar
• Saenz-Mendez P, Elmabsout AA, Savenstrand H, et al. Homology models of human all-trans retinoic acid metabolizing enzymes CYP26B1 and CYP26B1 spliced variant. J Chem Inf Model 2012;52:2631–7
   PubMed Web of Science ®Google Scholar
• Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005;61:831–6
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005;77:404–14
   PubMed Web of Science ®Google Scholar
• Karonen T, Filppula A, Laitila J, et al. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 2010;88:223–30
   PubMed Web of Science ®Google Scholar
• Niemi M, Tornio A, Pasanen MK, et al. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 2006;62:463–72
   PubMed Web of Science ®Google Scholar
• Foti RS, Honaker M, Nath A, et al. Catalytic versus inhibitory promiscuity in cytochrome P450s: implications for evolution of new function. Biochemistry 2011;50:2387–93
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metabol Dispos 2003;31:815–32
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003;43:443–69
   PubMed Web of Science ®Google Scholar
• Kosugi Y, Hirabayashi H, Igari T, et al. Evaluation of cytochrome P450–mediated drug–drug interactions based on the strategies recommended by regulatory authorities. Xenobiotica 2012;42:127–38
   PubMed Web of Science ®Google Scholar
• Sawyer PR, Brogden RN, Pinder RM, et al. Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs 1975;9:424–47
   PubMed Web of Science ®Google Scholar
• Schwartz EL, Hallam S, Gallagher RE, Wiernik PH. Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem Pharmacol 1995;50:923–8
   PubMed Web of Science ®Google Scholar
• Vanier KL, Mattiussi AJ, Johnston DL. Interaction of all-trans-retinoic acid with fluconazole in acute promyelocytic leukemia. J Pediatr Hematol/Oncol 2003;25:403–4
   PubMed Web of Science ®Google Scholar
• Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 2005;73:919–23
   PubMed Web of Science ®Google Scholar
• Menegola E, Broccia ML, Di Renzo F, Giavini E. Antifungal triazoles induce malformations in vitro. Reprod Toxicol 2001;15:421–7
   PubMed Web of Science ®Google Scholar
• Tiboni GM. Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos. Res Commun Chem Pathol Pharmacol 1993;79:381–4
   PubMedGoogle Scholar
• Tiboni GM, Giampietro F. Murine teratology of fluconazole: evaluation of developmental phase specificity and dose dependence. Pediatr Res 2005;58:94–9
   PubMed Web of Science ®Google Scholar
• Kizaki M, Ueno H, Yamazoe Y, et al. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 1996;87:725–33
   PubMed Web of Science ®Google Scholar
• Williams JB, Napoli JL. Inhibition of retinoic acid metabolism by imidazole antimycotics in F9 embryonal carcinoma cells. Biochem Pharmacol 1987;36:1386–8
   PubMed Web of Science ®Google Scholar
• Tiboni GM, Marotta F, Carletti E. Fluconazole alters CYP26 gene expression in mouse embryos. Reprod. Toxicol 2009;27:199–202
   PubMed Web of Science ®Google Scholar